Holen Sie sich die Stockscreener-App
0.00
100.00%
-5.11
Schlusskurs vom Vortag:
$5.11
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$342.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.20M
KGV:
0.00
EPS:
-2.15
Netto-Cashflow:
$57,000
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$11.55
Eliem Therapeutics Inc Stock (ELYM) Company Profile
Firmenname
Eliem Therapeutics Inc
Sektor
Branche
Telefon
877-354-3689
Adresse
2801 CENTERVILLE ROAD 1ST FLOOR, WILMINGTON
Vergleichen Sie ELYM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELYM
Eliem Therapeutics Inc
|
0.00 | 342.68M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.97 | 121.03B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.36 | 75.47B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.45 | 39.28B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.06 | 35.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.27 | 27.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eliem Therapeutics Inc Stock (ELYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Eliem Therapeutics Inc Aktie (ELYM) Neueste Nachrichten
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Bought by JPMorgan Chase & Co. - Defense World
Barclays PLC Acquires 36,316 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
Jane Street Group LLC Purchases New Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
Eliem Therapeutics Enters into Exclusive Licensing Agreement with Beijing Mabworks Biotech - Defense World
State Street Corp Has $1.60 Million Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
Eliem Therapeutics stock hits 52-week low at $1.86 amid market shifts - Investing.com Australia
Eliem Therapeutics stock hits 52-week low at $1.86 amid market shifts By Investing.com - Investing.com South Africa
Financial Analysis: TransCode Therapeutics (NASDAQ:RNAZ) & Eliem Therapeutics (NASDAQ:ELYM) - Defense World
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World
The Manufacturers Life Insurance Company Acquires Shares of 49,524 Eliem Therapeutics, Inc. (NASDAQ:ELYM) - Defense World
590,946 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Point72 Asset Management L.P. - MarketBeat
Janus Henderson Group PLC Has $18.30 Million Stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Samsara BioCapital LLC Has $13.28 Million Stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Parkman Healthcare Partners LLC Takes Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Ally Bridge Group NY LLC Purchases 729,292 Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Great Point Partners LLC Buys New Stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Eliem Therapeutics To Acquire Tenet Medicines - Contract Pharma
How To Trade (CLYM) - Stock Traders Daily
Climb Bio to present kidney disease treatment study - Investing.com India
Climb Bio to present kidney disease treatment study By Investing.com - Investing.com UK
Eliem Therapeutics Inc [ELYM] Shares Fall -0.97 % on Wednesday - Knox Daily
Eliem Therapeutics mounts corporate rebrand after pipeline overhaul, mass layoffs - FiercePharma
Eliem Therapeutics rebrands to Climb Bio, shifts focus to immune diseases - Investing.com
Eliem Therapeutics Changes Name to Climb Bio - Yahoo Finance
Eliem Therapeutics to change corporate name to Climb Bio - TipRanks
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - The Manila Times
Healthy Upside Potential: Eliem Therapeutics Inc (ELYM) - SETE News
Monitoring Eliem Therapeutics Inc (ELYM) after recent insider movements - Knox Daily
Eliem Therapeutics Inc (ELYM) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Ratio Analysis: Unpacking Eliem Therapeutics Inc (ELYM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Stock Position Decreased by Driehaus Capital Management LLC - MarketBeat
Selling Eliem Therapeutics Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m - Yahoo Finance
Eliem Therapeutics Inc (ELYM) can make a big difference with a little luck - SETE News
Eliem Therapeutics Inc (ELYM) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Affinity Asset Advisors LLC Takes $11.88 Million Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Trading (ELYM) With Integrated Risk Controls - Stock Traders Daily
500,000 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Ally Bridge Group NY LLC - MarketBeat
Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM) - Seeking Alpha
Closing Figures: Eliem Therapeutics Inc (ELYM)’s Positive Finish at 8.43, Up 1.81 - The Dwinnex
Eliem Therapeutics Inc (ELYM)’s stock price in review: A technical analysis - US Post News
Eliem therapeutics executive sells over $9,000 in company stock By Investing.com - Investing.com Australia
Eliem therapeutics executive sells over $9,000 in company stock - Investing.com
(ELYM) Trading Signals - Stock Traders Daily
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - GlobeNewswire
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 4.6% - MarketBeat
Finanzdaten der Eliem Therapeutics Inc-Aktie (ELYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):